Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Corticosteroid Therapy Guidelines

Disease-Specific Recommendations

  • The American Society of Hematology strongly recommends against prolonged courses (>6 weeks) of prednisone and favors short courses (≤6 weeks) for patients with Immune Thrombocytopenia (ITP) 1, 2
  • For patients with ITP requiring additional therapy after an initial 6-week course, consideration of alternative therapy is preferred over ongoing exposure to corticosteroids 1, 2
  • The British Society of Gastroenterology suggests offering systemic corticosteroids for no longer than 8 weeks for patients with Inflammatory Bowel Disease (Crohn's Disease) 3, 4
  • Repeated courses of steroids should be avoided unless futility of other effective therapies has been established and surgical options are not available for patients with Crohn's Disease 3, 4
  • For relapses of nephrotic syndrome, the KDIGO guidelines suggest that if a 6-month cyclical corticosteroid/alkylating-agent regimen was used for initial therapy, the regimen should be repeated only once for treatment of a relapse in patients with Membranous Nephropathy 5
  • In children with membranous nephropathy, no more than one course of the cyclical corticosteroid/alkylating-agent regimen should be given 5

General Principles for Minimizing Harm

  • Courses longer than 6 weeks are associated with a large risk of harm and likelihood of adverse events, including hypertension, hyperglycemia, sleep and mood disturbances, gastric irritation, glaucoma, myopathy, and osteoporosis 1, 2, 6
  • The risk of adverse effects increases significantly with doses >20 mg/day for more than 18 months, with severe adverse effects occurring in about 15% of patients 6

Critical Pitfalls to Avoid

  • Do not use arbitrary time intervals between courses—the decision should be based on disease response, alternative treatment options, and cumulative steroid exposure 1, 2, 3, 4
  • Do not continue corticosteroids beyond 6-8 weeks without reassessing the need for alternative immunosuppressive therapy 1, 2, 3, 4
  • Monitor for infection risk, particularly with doses ≥20 mg prednisone-equivalent for ≥4 weeks, and consider Pneumocystis jirovecii pneumonia prophylaxis 6